NASDAQ
67.63USD
-1.01 (-1.48%)
We have scored 18 news catalysts on Liquidia Corporation (LQDA) over the past 12 months. The biggest single-day move next to one of them came Aug 12, 2026, when LQDA closed −10.5%: “Liquidia Q2 Earnings Call Highlights”. Coverage across the window leans positive (average ticker sentiment +0.69). Most of the impact sits in sector healthcare and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6B
P/E
—
EPS
—
Beta
0.54
52W range
21.15-93.61
Day range
67.10–68.60
Open
68.60
Prev close
68.64
Volume
528.5K
Avg volume
1.7M
Dividend
0.00
IPO
2018-07-26
Analysts publish price targets on LQDA, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
12 analyst price targets from $28 to $130
as of 2026-09-13
The market is 38% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Liquidia Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for LQDA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
The reconstruction
The price sits at the 17th percentile of published models, 38% below the median target, meaning it accepts the near-consensus base case but refuses to pay for the steep growth required by the bulls or the worst-case legal outcomes projected by the bears.
What the disagreement turns on
Whether YUTREPIA's prescription volume can sustain enough quarterly growth to approach the $1 billion revenue threshold in 2027, a question that unit volume data can directly address but pricing and legal outcome data cannot.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
